MedTrace Logo

SPSIP Block for Pain Control After Breast Reduction Surgery

NCT07657949 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-06-18

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether an ultrasound-guided serratus posterior superior intercostal plane block (SPSIP block) can lower the need for opioid pain medicine after breast reduction surgery.

The main question it aims to answer is: Does adding an SPSIP block to standard anesthesia and pain treatment lower opioid use during the first 24 hours after surgery? Researchers will compare participants who receive standard anesthesia and pain treatment with participants who receive standard anesthesia and pain treatment plus an SPSIP block.

Participants will:

* Have planned bilateral breast reduction surgery under general anesthesia
* Be randomly assigned to the SPSIP block group or the control group
* Receive standard local anesthetic infiltration during surgery and standard pain treatment after surgery
* Have their pain score and pain medicine use recorded during the first 24 hours after surgery
* Be followed for safety and complications for 30 days after surgery

Conditions

  • Postoperative Pain Breast Reduction
  • Mammaplasty
  • Analgesia
  • Nerve Block
  • Opioid Consumption, Postoperative

Interventions

PROCEDURE

Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block

Bilateral ultrasound-guided serratus posterior superior intercostal plane block will be performed after induction of general anesthesia and before surgical local anesthetic infiltration and skin incision.

OTHER

Standard Perioperative Pain Treatment

Participants will receive standard general anesthesia, standardized surgical local anesthetic infiltration, and standard postoperative multimodal pain treatment with rescue analgesia when clinically needed.

Sponsors & Collaborators

  • Cumhuriyet University Hospital

    lead OTHER

Principal Investigators

  • Handan Derebaşınlıoğlu, Associate Professor · Cumhuriyet University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2027-07-30
Completion
2027-08-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07657949 on ClinicalTrials.gov